Trial Profile
Volanesorsen (ISIS 304801) Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS)
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 20 Sep 2021
Price :
$35
*
At a glance
- Drugs Volanesorsen (Primary)
- Indications Hyperlipoproteinaemia type I
- Focus Expanded access; Therapeutic Use
- Sponsors Akcea Therapeutics
- 10 Sep 2021 Status changed from recruiting to completed.
- 18 Sep 2020 According to an Akcea Therapeutics media release, Since initiation of the EAMS, 22 patients with FCS have been treated with volanesorsen, at no cost to the NHS.
- 08 May 2018 New trial record